News
APLS
--
0.00%
--
Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
GlobeNewswire · 5h ago
Global Led Detection System Market 2021, Segmentation Application, Technology & Market Analysis Research Report to 2025
Jan 25, 2021 (The Expresswire) -- Global “Led Detection System market” competitive landscape provides particulars and data information by players. The report...
The Express Wire · 1d ago
Wet Macular Degeneration Market Outlook 2026: Top Companies, Trends and Growth Factors Details for Business Development
Jan 22, 2021 (The Expresswire) -- The global “Wet Macular Degeneration Market” Report deliver comprehensive analysis of the market structure along with...
The Express Wire · 4d ago
Global Terahertz Components and Systems Market 2021 Research Reports, Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by 360 Market Updates
Jan 22, 2021 (The Expresswire) -- 360 Market Updates adds Global Terahertz Components and Systems Market 2021 report that offers an exhaustive coverage of...
The Express Wire · 4d ago
Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a virtual investor event titled Pegcetacoplan: Advancing the First Potential Treatment for Geog...
GlobeNewswire · 5d ago
Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a virtual investor event titled Pegcetacoplan...
GlobeNewswire · 5d ago
Terahertz Components and Systems Market 2021 Latest Report Covering Key vendors, Price Trends, Gross Margin, Influence of COVID-19 and Forecast To 2025
Jan 21, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Terahertz Components and Systems Market”...
The Express Wire · 5d ago
Terahertz Components and Systems Market Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2024
Jan 20, 2021 (AmericaNewsHour) -- Global Terahertz Components and Systems Market is estimated to reach $433.6 Million by 2024 with CAGR of 26.8% between 2016...
AmericaNewsHour · 6d ago
Operator Training Simulator Market Size, Trends, Companies, Driver, Segmentation, Forecast to 2025
Jan 20, 2021 (Market Insight Reports) -- As per the report titled 'Operator Training Simulator Market Size By Component, By Simulation Environment, By...
Market Insight Reports · 6d ago
Global Terahertz Radiation System Market Size 2021-2025 By Development History, Growth Factor, Prominent Players Updates, Business Analysis, Share Estimation till 2025 | Industry Research Biz
Jan 20, 2021 (The Expresswire) -- The “Terahertz Radiation System Market” Research Report 2021-2025 is a specialized and in-depth study of the Terahertz...
The Express Wire · 6d ago
ARA-Designed Utah Tech Corridor Reconstruction Project Completed
Salt Lake City, Utah, Jan 18, 2021 (GLOBE NEWSWIRE via COMTEX) -- Salt Lake City, Utah, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Applied Research Associates, Inc....
GlobeNewswire · 01/18 16:14
Unattended Ground Sensors (UGS) Market Analysis, Size, Share, Trends, Analysis and Growth by Forecast to 2025
Heraldkeepers · 01/18 13:20
ARA-Designed Utah Tech Corridor Reconstruction Project Completed
Applied Research Associates, Inc. (ARA) was part of a team of designers and contractors who recently completed a large, high-priority design/build project on Utah's Tech Corridor on I-15. The project is located south of Salt Lake City for the Utah Departme...
GlobeNewswire · 01/18 13:00
Global Led Detection System Market Size 2021 | Industry Statistics, Emerging Technologies, Business Challenges, Covid-19 Outbreak, Segmentation, Explosive Factors of Revenue Expansion and Strategies 2025
Jan 12, 2021 (The Expresswire) -- The “Led Detection System Market” Research Report 2021-2025 is a specialized and in-depth study of the Led Detection System...
The Express Wire · 01/12 05:04
Light Sensors Market Drivers, Latest Innovations and Industry Status 2021 to 2030 | Northrop Grumman Corporation, Textron Inc
A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2030 by discloses a succinct analysis of the regional spectrum, market size, and revenue forecast about the market. This ...
marketresearch.biz · 01/11 06:38
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7)
Benzinga · 01/08 12:25
Apellis to exchange shares for ~$107.5M principal notes
Apellis Pharmaceuticals (APLS) certain holders of 3.5% convertible senior notes due 2026 to exchange ~$107.5M in aggregate principal amount of notes held by them for 2.2M common shares.The exchange transactions
Seekingalpha · 01/07 12:07
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreemen...
GlobeNewswire · 01/07 11:55
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible ...
GlobeNewswire · 01/07 11:55
Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a...
GlobeNewswire · 01/05 12:00
Webull provides a variety of real-time APLS stock news. You can receive the latest news about Apellis through multiple platforms. This information may help you make smarter investment decisions.
About APLS
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.